Astex Therapeutics Company Profile

10:55 EST 15th December 2018 | BioPortfolio

Astex was founded in 1999 by Harren Jhoti, PhD, former Head of Structural Biology and of UK Bioinformatics at GlaxoWellcome, together with Professor Sir Tom Blundell, FRS, Professor Chris Abell, (both of University of Cambridge) and Dr Roberto Solari, currently Chief Executive of Medical Research Council Technology. The co-founders' vision for Astex was to develop the use of high-throughput X-ray crystallography in a novel fragment-based approach to drug discovery. In only five years, the consistent vision of the co-founders has materialized into a leading European biotechnology company that has pioneered and successfully established this new approach to drug discovery.
Since Astex began its operations it has raised more than £51 million in two principal funding rounds from leading biotech investors in the US and in Europe. Astex operates its business from a purpose-built, 36,000 sq.ft. research and development facility on the Cambridge Science Park in the UK and has a staff of approximately 95 almost 60 of whom have PhD's.


436 Cambridge Science ParkMilton Road
United Kingdom


Phone: 44 (0)1223 226200
Fax: 44 (0)1223 226201

News Articles [712 Associated News Articles listed on BioPortfolio]

Martin Buckland talks about the great potential created by the recent merger between SuperGen Inc. and Astex Therapeutics

In this episode of PharmaTelevision News Review, Fintan Walton talks to Martin Buckland, CBO of Astex Therapeutics

Astex Pharmaceuticals: James Manuso & Harren Jhoti introduce the newly formed Astex Pharmaceuticals

In this episode of PharmaTelevision News Review, Paul Larsmon talks to James Manuso Chairman & CEO and Harren Jhoti President of Astex Pharmaceuticals.

Astex Pharma’s Leukemia Drug Fails Clinical Trial

Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical, indicated their guadecitabine (SGI-110) missed its co-primary endpoints in acute myeloid leukemia (AML).

Astex and Otsuka Announce that Guadecitabine Fails to Meet Endpoints in Late-Stage AML Study

otsuk PLEASANTON, Calif. & TOKYO–(BUSINESS WIRE)–Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from th...

Otsuka/Astex AML Candidate Guadecitabine Fails Phase III Trial

Otsuka Pharmaceutical and its Astex Pharmaceuticals subsidiary acknowledged that their cancer candidate guadecitabine (SGI-110) has failed a Phase III trial assessing the DNA methyltransferase inhibit...

GE Healthcare Financial Services: Debt Financing and the Importance of IP

In this exclusive interview, Fintan Walton talks to Marcus O’Neill, VP Life Science Finance at GE Healthcare Financial Services. The topic of this week’s discussion is debt financing, or ‘ventur...

Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASTRAL-1 Study of ...


Astex Pharmaceuticals Inc Strategic SWOT Analysis Review [Report Updated: 08052018] Prices from USD $125

Astex Pharmaceuticals Inc Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a deta...

PubMed Articles [461 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [165 Associated Clinical Trials listed on BioPortfolio]

Guadecitabine Extension Study

This is a multicenter, open-label extension study for subjects who participated in a previous Astex-sponsored guadecitabine clinical study (including but not limited to SGI-110-01, SGI-110...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1288 Associated Companies listed on BioPortfolio]

Astex Therapeutics

Astex was founded in 1999 by Harren Jhoti, PhD, former Head of Structural Biology and of UK Bioinformatics at GlaxoWellcome, together with Professor Sir Tom Blundell, FRS, Professor Chris Abell, (both...

Astex Technology Limited

Astex Technology is a structure-based drug discovery company pioneering the use of high throughput X-ray crystallography for the rapid identification of novel drug candidates. The company's unique st...

Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. The Company is developing a proprietary pipeline of novel cancer...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Astex Therapeutics" on BioPortfolio

We have published hundreds of Astex Therapeutics news stories on BioPortfolio along with dozens of Astex Therapeutics Clinical Trials and PubMed Articles about Astex Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Astex Therapeutics Companies in our database. You can also find out about relevant Astex Therapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Corporate Database Quicklinks

Searches Linking to this Company Record